Effect of Low-Level Laser Therapy in Treatment of Chemotherapy Induced Oral Mucositis
Rezk-Allah SS, Abd Elshaf HM, Farid RJ, Hassan MAE, Alsirafy SA
Journal of lasers in medical sciences · 10 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2019-02-25 · J Lasers Med Sci · vol. 10 · número 2 · págs. 125–130
- Citado
- 49 citas · más que el 89% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 28 trabajos
- Acceso
- Acceso abierto (publicación gratuita) · CC-BY-NC
- Áreas de investigación
- Oral health in cancer treatment · Cancer Diagnosis and Treatment · Head and Neck Cancer Studies
- Palabras clave
- Medicine, Mucositis, Low level laser therapy, Chemotherapy, Head and neck cancer, Internal medicine, Cancer, Surgery, Gastroenterology, Laser therapy
5 autores
- Soheir Shehata Rezkallah🇪🇬Cairo University
- Heba Mohamed Abd Elshafi🇪🇬Cairo University
- Reem Jan Farid🇪🇬Cairo University
- Mohamed Abd Elrahman Hassan🇪🇬Cairo University
- Samy A. Alsirafy🇪🇬Cairo University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Introduction: Oral mucositis (OM) is an unavoidable condition of the oral cavity that accompanies chemotherapy for various malignant cases. Chemotherapy-induced oral Mucositis (COM) is a frequent complication due to mucotoxic drugs and is known to deteriorate the general health significantly, while negatively affecting the quality of life (QOL). Studies have reported that low-level laser therapy (LLLT) promotes the tissue healing. The objective of the present study was to explore the efficacy of gallium-arsenide (GaAs) laser in treating COM and its impact on inflammatory cytokine levels in patients receiving chemotherapy for various malignancies. Methods: A total of 80 patients with COM received LLLT 6 days/week. OM was graded according to the World Health Organization (WHO) grading scale. The outcome parameters were the serum levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) measured before, during and after administration of LLLT. Results: After LLLT, a significant decrease was found in the mean values of mucositis grade from 2.35 ± 0.695 to 1.13 ± 0.333 after (P P = 0.0045), but not in head and neck cancer and lymphoma patients. A significant reduction was also found in IL-6 level after treatment among head and neck and breast cancer patients (P = 0.0307 and 0.019, respectively). Conclusion: The use of GaAs LLLT in treating COM in patients with various malignancies is well tolerated by patients, it results in improvement of mucositis, however; mechanism of action does not seem to be completely linked to the change of pro or anti-inflammatory cytokines.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.